NIT
ADVM

NumerixS Investment Technologies’s Adverum Biotechnologies ADVM Stock Holding History

NumerixS Investment Technologies’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,883
Closed -$393K – 21
2020
Q2 		$393K Buy
+1,883
New +$333K 0.11% 213

Other funds holding ADVM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

NumerixS Investment Technologies's ADVM Position: Q3 2020 in Review

NumerixS Investment Technologies sold out of Adverum Biotechnologies (ADVM) in Q3 2020, closing a stake of 1,883 shares — an estimated $393K sold.

NumerixS Investment Technologies first reported a position in ADVM in Q2 2020 and held it in 1 quarter. The position peaked at $393K in Q2 2020. 160 funds tracked by Wall St. Rank hold ADVM as of Q3 2020.

  • NumerixS Investment Technologies reported no remaining Adverum Biotechnologies position as of Q3 2020 after selling out during the quarter.
  • NumerixS Investment Technologies sold 1,883 Adverum Biotechnologies shares in Q3 2020, an estimated $393K.
  • NumerixS Investment Technologies first reported a position in Adverum Biotechnologies in Q2 2020 and held it in 1 quarter.
  • NumerixS Investment Technologies's Adverum Biotechnologies position peaked at $393K in Q2 2020.
  • 160 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2020.

Based on NumerixS Investment Technologies's 13F filing for Q3 2020.